Overview

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

Status:
Completed

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Ramipril